Abzena PLC Termination of licence agreement (1930K)

TIDMABZA

RNS Number : 1930K

Abzena PLC

09 April 2018

Abzena plc

Termination of licence agreement

Cambridge, UK, 9 April 2018 - Abzena plc (AIM: ABZA, 'Abzena', the 'Company' or the 'Group'), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, has received notice from Halozyme Therapeutics, Inc ('Halozyme'), of the termination of the Collaboration and Licence Agreement relating to Halozyme's use of the Group's ThioBridge linker technology for the development of antibody drug conjugate products.

Under the Agreement, Halozyme had progressed the development of HTI-1511, an anti-EGFR antibody drug conjugate product. Preclinical results from this program were presented at the 2017 meeting of the American Association for Cancer Research reporting the significant activity of HTI-1511 against multiple tumour types and a safety profile suitable for candidate nomination.

-Ends-

Enquiries:

 
Abzena plc 
 John Burt, Chief Executive 
 Officer 
 Julian Smith, Chief Financial 
 Officer                              [phone] 
Numis (Nominated Adviser and 
 Broker) 
 Clare Terlouw / James Black 
 / Paul Gillam                        [phone] 
N+1 Singer (Joint Broker) 
 Aubrey Powell / Liz Yong             [phone] 
Instinctif Partners                   [phone] 
 Melanie Toyne Sewell / Alex           [e-mail] 
 Shaw 
 

Notes to Editors

About Abzena

Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.

The term 'Abzena inside' is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies(TM) and ThioBridge(TM) Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on 'Abzena inside' products.

Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA):

-- Immunology research studies, including immunogenicity assessment of candidate biopharmaceutical products;

   --      Protein engineering to create humanized antibodies and deimmunised therapeutic proteins; 
   --      Cell line development for the manufacture of recombinant proteins and antibodies; 

-- Contract process development and GMP manufacture of biopharmaceuticals, including monoclonal antibodies and recombinant proteins for preclinical and clinical studies;

-- Contract synthetic chemistry and bioconjugation research services, focused on antibody-drug conjugates (ADCs);

-- Proprietary site-specific conjugation technologies and novel payloads for ADC development; and

   --      GMP manufacturer of ADC linkers, payloads & combined linker-payloads. 

For more information, please see www.abzena.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

AGRFKFDBKBKBCQK

(END) Dow Jones Newswires

April 09, 2018 03:25 ET (07:25 GMT)